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OBJECTIVE — The purpose of this study was to determine the impact of white-coat hyper-
tension (WCH) on microvascular complications in type 2 diabetes.
RESEARCH DESIGN AND METHODS — A cross-sectional study was conducted in
normotensive patients and patients with WCH selected from a cohort of 319 type 2 diabetic
patients. Normotension was deﬁned by ofﬁce blood pressure 140/90 mmHg and daytime
blood pressure 135/85 mmHg on ambulatory blood pressure monitoring (ABPM). WCH was
deﬁned as ofﬁce blood pressure 140/90 mmHg and daytime blood pressure 135/85 mmHg
on ABPM. Subjects were evaluated for diabetic nephropathy (24-h urinary albumin excretion
rate) and diabetic retinopathy (classiﬁed according to the Global Diabetic Retinopathy Group).
RESULTS — Forty-sixtype2diabeticpatientshadWCH(14.4%;meanage56.6years;45.3%
men) and 117 had normotension (36.6%; mean age 55.8 years; 37.5% men). These groups did
not differ in clinical and main laboratory characteristics. Systolic ABPM (24-h: 124.7  6.7 vs.
121.0  8.5 mmHg, P  0.01 and daytime: 126.6  7.2 vs. 123.2  8.2 mmHg, P  0.01) and
bloodpressureloadswerehigherinsubjectswithWCHthaninthenormotensivesubjects.WCH
was associated with an increased risk for macroalbuminuria (odds ratio 4.9 [95% CI 1.3–18.7],
P  0.01). On multivariate analysis models, WCH was associated with macroalbuminuria (2.0
[1.3–3.2], P  0.02) and increased the risk for both nonproliferative and proliferative diabetic
retinopathy(2.7[1.2–6.6],P0.02foranydegreeofdiabeticretinopathy)afteradjustmentsfor
confounding factors.
CONCLUSIONS — Type 2 diabetic patients with WCH have an increased risk for diabetic
retinopathy and diabetic nephropathy. Therefore, WCH should not be considered a harmless
condition, and treatment should be considered.
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H
ypertensionisamajorriskfactorfor
both the onset and progression of
chronic diabetes complications,
and its treatment can prevent deleterious
micro- and macrovascular outcomes
(1,2). Abnormalities in blood pressure
homeostasis demonstrated on ambula-
tory blood pressure monitoring (ABPM)
haveabettercorrelationwithtargetorgan
lesions than ordinary ofﬁce blood pres-
sure measurements (3,4).
Hypertensive patients with normal
blood pressure values on ABPM, namely
“white-coat hypertension” (WCH), have
beenhistoricallyconsideredtohavealow
risk proﬁle for vascular complications.
Consequently, subjects with WCH have
been followed as normotensive individu-
als and, most of the time, do not receive
treatment. However, emerging data from
general population studies associate
WCH with cardiac structural abnormali-
ties (5) as well as increased risk for stroke
and cardiovascular events (5).
In type 1 diabetic patients, WCH is
associated with the subsequent develop-
ment of sustained hypertension and mi-
croalbuminuria (6). However, the
repercussions of WCH in type 2 diabetic
patients have not been reported. There-
fore, the aim of this study was to charac-
terize type 2 diabetic patients with WCH
and determine its effects on chronic dia-
betes complications.
RESEARCH DESIGN AND
METHODS— A cross-sectional study
was performed with normotensive pa-
tients (n  117) and patients with WCH
(n  46) selected from a cohort of 319
type2diabeticpatientswhohadregularly
attended the diabetes outpatient clinic at
Hospital de Clínicas de Porto Alegre,
Porto Alegre, Brazil, since 1994. Normo-
tension was deﬁned by an ofﬁce blood
pressure 140/90 mmHg on at least two
occasions during a 6-month period and
daytime blood pressure means 135/85
mmHg on ABPM; WCH was deﬁned by
an ofﬁce blood pressure 140/90 mmHg
on at least two occasions during a
6-month period and daytime blood pres-
sure means 135/85 mmHg on ABPM.
None of the patients were taking antihy-
pertensivemedicationsatthetimeofeval-
uation, and those who were using any
drug with an antihypertensive effect had
the medication suspended 1 week before
the evaluation. Patients with serum creat-
inine 1.5 mg/dl, other renal diseases,
cardiac arrhythmia, autonomic symp-
toms (chronic diarrhea, syncope, or vaso-
motor symptoms), or orthostatic
hypotension were excluded.
The study protocol was approved by
the ethics committee of the hospital.
Written informed consent was obtained
from all patients.
Clinical evaluation
Patientsunderwentaninterviewandclin-
ical examination to record demographic
and anthropometric data, as described
previously (7). Blood pressure evalua-
tions were performed 1 week after with-
drawal of all medications with an
antihypertensiveeffect.Theanalyseswere
performedonthebasisofthemeanoftwo
ofﬁce blood pressure values (measured
with a mercury sphygmomanometer us-
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sitting position, after a 5-min rest, on the
same day as the ABPM). ABPM was ob-
tained by oscillometry (Spacelabs 90207
serial nos. 207/024751 and 207/038016
with calibration certiﬁcation), with a 15-
min interval in the daytime and 20-min
interval in the nighttime period. ABPM
was performed on an ordinary workday,
and patients were advised to maintain
their usual daily activities. Sleep time was
recorded as the period between the time
whenthepatientwenttobedandthetime
when the patient woke up the next morn-
ing. The means of 24-h, daytime, and
nighttime systolic and diastolic blood
pressurewererecorded,aswellassystolic
and diastolic blood pressure loads (per-
centage of 24-h and daytime blood pres-
sure 140/90 mmHg and nighttime
blood pressure 120/80 mmHg) and
pulse pressure (systolic minus diastolic
blood pressure). The difference between
theofﬁcesystolicbloodpressureandday-
time systolic blood pressure means was
included in the analysis and described as
the “white-coat effect.”
Blood pressure was evaluated during
exercise in a subset of patients (normo-
tension n  38 and WCH n  18) by an
exercise treadmill test (standard Bruce
protocol using a computerized database)
(8). Midway through each stage of the ex-
ercise protocol, at peak exercise and at 1,
2, and 4 minutes after cessation of exer-
cise, data on symptoms, heart rate and
rhythm, blood pressure, and estimated
workload (based on standards tables) in
METs (1 MET  3.5 ml of oxygen uptake
per kg body weight per min) were col-
lected.Thebloodpressureincrementwas
deﬁned as the difference between the
peak exercise blood pressure and resting
blood pressure.
Laboratory methods
The urinary albumin excretion rate
(UAER) was measured (values expressed
in micrograms per minute) by immuno-
turbidimetry (MicroAlb Sera-Pak immu-
nomicroalbuminuria [Bayer, Tarrytown,
NY] on a Cobas Mira Plus analyzer
[Roche]; mean intra-assay and interassay
coefﬁcients of variation of 4.5 and 7.6%,
respectively) in at least two 24-h collec-
tions over the preceding 6 months (9).
A1C was measured by a high-perfor-
mance liquid chromatography system
(reference range 4.7–6.0%) (Merck-
Hitachi 9100; Merck, Darmstadt, Ger-
many). Fasting plasma glucose was
measured by the glucose-peroxidase col-
orimetricenzymaticmethod(Biodiagnos-
tica). Serum creatinine was measured by
the Jaffe method, serum total cholesterol
and triglycerides were measured by enzy-
matic-colorimetricmethods(MerckDiag-
nostica,Darmstadt,Germany;Boeringher
Mannheim, Buenos Aires, Argentina),
andHDLcholesterolwasmeasuredbythe
homogeneous direct method (ADVIA
1650 AutoAnalyzer). LDL cholesterol
was calculated using the Friedenwald
formula.
Outcomes
Diabetic retinopathy. Fundus eye ex-
amination was performed by an experi-
enced ophthalmologist after mydriasis,
and diabetic retinopathy was classiﬁed
using the scale developed by the Global
Diabetic Retinopathy Group (10). The di-
abetic retinopathy level was based on the
most severe degree of retinopathy in the
worst eye affected.
Diabetic nephropathy. UAER was mea-
sured in 24-h sterile urine samples. Pa-
tients were classiﬁed, according to UAER,
into three groups: normoalbuminuric
(UAER 20 g/min), microalbuminuric
(UAER20–199g/min),andmacroalbu-
minuric (UAER 200 g/min). The glo-
merular ﬁltration rate was estimated
using the formula of the Modiﬁcation of
Diet in Renal Disease study: 186  [(se-
rum creatinine)
1.154  (age)
0.203 
(0.742, if female)  (1.210, if African de-
scendant)] (11).
Statistical analysis
Allanalyseswereperformedusingthesta-
tistical package SPSS (version 14.0; SPSS,
Chicago, IL). Data are expressed as
means  SD, except for UAER, triglycer-
ides,bloodpressureloads,andwhite-coat
effect values, which are median (inter-
quartile range). Quantitative variables
without a normal distribution were log-
transformed. Student’s t test or 
2 tests
were used to compare clinical and labora-
tory data. Pearson’s test was used to study
correlations among clinical variables.
Multiple linear regressions were per-
formed with UAER as the dependent
variable. Macroalbuminuria, microalbu-
minuria, and diabetic retinopathy were
analyzed as dependent variables in sepa-
rate models of logistic regression. P 
0.05 (two-tailed) on the univariate analy-
sis were considered signiﬁcant.
RESULTS— WCH was found in 46
(14.4%; mean age 56.6 years; 45.3%
men) and normotension in 117 (36.6%;
mean age 55.8 years; 37.5% men) type 2
diabetic patients of the overall cohort.
Thesegroupswerenotdifferentregarding
age, diabetes duration, anthropometric
characteristics, renal function, glycemic
control, or lipid proﬁle (Table 1). Inter-
estingly, there were more active smokers
among the normotensive patients than
among the patients with WCH.
The 24-h systolic blood pressure
means on ABPM were higher in the WCH
group than in the normotensive group
Table 1—Clinical and laboratory characteristics according to blood pressure classiﬁcation
Normotension
White-coat
hypertension P value
n 117 46
Male subjects 53 (45.3) 17 (37.5) 0.38
Age (years) 56.6  10.2 55.8  9.6 0.65
Diabetes duration (years) 9.8  7.9 10.9  7.0 0.38
BMI (kg/m
2) 28.2  5.0 28.8  5.2 0.55
Waist circumference (cm) 97.7  11.1 98.0  12.5 0.62
Smoking habit 25 (21.6) 4 (8.9) 0.004
A1C (%) 6.9  1.8 7.1  1.8 0.61
Fasting plasma glucose (mg/dl) 159.4  70.5 155.2  57.0 0.73
Total cholesterol (mg/dl) 191.3  39.4 194.0  48.2 0.73
HDL (mg/dl) 48.2  13.1 47.8  10.1 0.87
LDL (mg/dl) 112.9  33.1 114.0  39.0 0.86
Triglycerides (mg/dl)* 122 (102) 121 (140) 0.86
Creatinine (mg/dl) 0.85  0.2 0.82  0.1 0.33
Estimated glomerular ﬁltration
rate (ml/min per 1.73 m
2) 90.8  24.4 92.9  23.9 0.63
Data are n (%) or means  SD unless otherwise indicated. *Median interquartile range.
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0.01). Daytime systolic blood pressure
(126.67.2vs.123.28.2mmHg,P
0.01), pulse pressure (24 h 52  8.1 vs.
48.67.6mmHg,P0.01anddaytime
51.7  8.2 vs. 48.8  8.8 mmHg, P 
0.05), and all blood pressure loads (24 h,
daytime, and nighttime) followed the
same pattern (Table 2).
WCH and microvascular
complications
UAER was higher in patients with WCH
than in normotensive patients (median
15.5 [interquartile range 45.3] vs. 7.4
[15.2] g/min, P  0.01). Moreover, the
proportions of micro- and macroalbu-
minuric patients were higher in the WCH
group(normoalbuminuria57.1%,micro-
albuminuria 28.6%, and macroalbumin-
uria 14.3%) than in the normotensive
group(normoalbuminuria74.3%,micro-
albuminuria 21.9%, and macroalbumin-
uria 3.8%, P for trend  0.03). WCH
conferred an increased risk for macro-
albuminuria(oddsratio[OR]4.9[95%CI
1.3–18.7], P  0.01), but not for micro-
albuminuria(Fig.1).Thisassociationwas
sustained after adjustments for diabetes
duration and A1C in the multivariate re-
gressionmodel(2.0[1.3–3.2],P0.02).
Similarly, a higher prevalence of dia-
betic retinopathy was found in patients
with WCH than in normotensive patients
(57.9 vs. 34.4%, P  0.01). The presence
of WCH increased the risk for both
nonproliferativeandproliferativediabetic
retinopathy (Fig. 1). Moreover, WCH in-
creased by 2.7-fold (95% CI 1.2–6.6) the
chance for any degree of diabetic retinop-
athy after adjustment for diabetes dura-
tion and A1C (P  0.02). Including
current smoking habit in the multivariate
regressionmodels(forbothUAERanddi-
abetic retinopathy as outcomes) did not
materially change the results.
The white-coat effect and
microvascular complications
To evaluate whether the magnitude of
WCH was associated with UAER, the dif-
ference between the ofﬁce systolic blood
pressure and daytime systolic blood pres-
sure means (white-coat effect) was calcu-
lated. There was a correlation between
this variable and UAER (r  0.325, P 
0.04).Inaddition,inthelinearregression
model, the white-coat effect was associ-
ated with UAER independently of diabe-
tes duration and A1C value (standardized
	-coefﬁcient 0.197, P  0.03). In addi-
tion, patients with proliferative diabetic
retinopathy (n  26) presented with
higher white-coat effect values (median
13 [interquartile range 26] mm Hg) than
those without diabetic retinopathy or
nonproliferative diabetic retinopathy (3
[21] mmHg, P  0.04).
WCH and response to exercise
Thirty-eight normotensive patients and
18 patients with WCH performed exer-
cise testing. The WCH group reached
higher blood pressure maximum levels
(systolic 183.7  22.2 vs. 166.8  16.1
mmHg, P  0.002; diastolic 81.5  7.3
vs.76.48.1mmHg,P0.02)thanthe
normotensive group. METs and peak ex-
ercise heart rate were similar between the
Figure 1—WCH OR for type 2 diabetes chronic complications.
Table 2—Blood pressure characteristics according to blood pressure classiﬁcation
Normotension
White-coat
hypertension P value
n 117 46
Ofﬁce
Systolic blood pressure (mmHg) 123.5  10.8 149.7  11.7 NA
Diastolic blood pressure (mmHg) 75.9  7.3 88.5  9.2 NA
Pulse pressure (mmHg) 47.5  9.2 61.1  13.8 0.001
24 h
Systolic blood pressure (mmHg) 121.0  8.5 124.7  6.7 0.01
Diastolic blood pressure (mmHg) 72.4  6.0 72.7  6.2 0.76
Pulse pressure (mmHg) 48.6  7.6 52  8.1 0.01
Systolic blood pressure load (%) 11.9 (24.2) 22.2 (21) 0.01
Diastolic blood pressure load (%) 3.3 (8.7) 6.3 (12.3) 0.03
Daytime
Systolic blood pressure (mmHg) 123.2  8.2 126.6  7.2 0.01
Diastolic blood pressure (mmHg) 74.8  6.4 74.8  7.0 0.97
Pulse pressure (mmHg) 48.8  8.8 51.7  8.2 0.05
Systolic blood pressure load (%) 5.3 (13.2) 12.5 (19.3) 0.01
Diastolic blood pressure load (%) 2.3 (7.3) 4.5 (9.4) 0.04
Nighttime
Systolic blood pressure (mmHg) 116.6  11.8 119.8  9.5 0.07
Diastolic blood pressure (mmHg) 66.8  7.6 67.9  7.3 0.39
Pulse pressure (mm Hg) 49.7  8.6 51.9  9.5 0.17
Systolic blood pressure load (%) 27.6 (64) 46.2 (34.4) 0.02
Diastolic blood pressure load (%) 2 (13.5) 6.7 (17.3) 0.06
Data are means  SD or median (interquartile range).
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during the test (Table 3).
CONCLUSIONS — In this sample of
type 2 diabetic subjects, the prevalence of
WCH was 14%. The clinical and labora-
tory characteristics of these subjects did
not differ from those of the normotensive
group, but higher blood pressure levels
were demonstrated during both the
ABPM and exercise test. The presence of
WCH increased the risk for diabetic reti-
nopathy and macroalbuminuria by 2.7
and 2.0 times, respectively, after adjust-
ment for confounders. In addition, the
white-coateffectwaspositivelycorrelated
with UAER and also associated with pro-
liferative diabetic retinopathy.
WCH is a common ﬁnding in both
the hypertensive and general population,
being described in 21–30 and 12%, re-
spectively (5,12–14). The prevalence of
WCH was believed to be increased in pa-
tients with diabetes, reaching up to 74%
in hypertensive type 1 diabetic patients
(15) and 51% in hypertensive type 2 dia-
betic patients (16). Subsequently, these
ﬁndings were challenged in type 2 dia-
betic patients. Nielsen et al. (17) found a
WCH prevalence of 23% in normoalbu-
minuric individuals, 8% in microalbu-
minuric patients, and 9% in
macroalbuminuric patients. The overall
prevalence of 14% in type 2 diabetic pa-
tients of this study is the same as that
found in the general population and is
close to the data of Nielsen et al. (17).
Differences concerning the deﬁnition of
WCH (systolic/diastolic 24-h blood pres-
sure means or daytime systolic/diastolic
blood pressure means) may have contrib-
uted to some of the disparities between
the studies. Moreover, the prevalence of
WCH changes according to age, sex, and
ethnicity.
WCH has been historically treated as
a benign phenomenon, as previous stud-
ies have demonstrated a lower risk for ad-
verse events in this group than in those
with sustained hypertension (18,19).
This concept has been questioned lately,
as WCH has come to be associated with
greater left ventricular hypertrophy (5)
and cardiovascular mortality (12,20,21).
In the general population, some studies
haveshownsimilarclinicalcharacteristics
in individuals with WCH and normoten-
siveindividuals(22),whereasothershave
described a higher cardiovascular risk
proﬁle in subjects with WCH (23,24). Of
interest is the fact that a current smoking
habitwasmorefrequentinthenormoten-
sive group. This could reﬂect a lifestyle
change in subjects considered to be
sicker, because they have increased levels
intheofﬁce.However,inanalysisofother
vascular risk factors, such as dyslipide-
mia, obesity, glycemic control, and ab-
dominalcircumference,nodifferencewas
observedbetweengroups.Evenintheab-
sence of a worse risk proﬁle, WCH was
associated with diabetic retinopathy and
diabetic nephropathy. To the best of our
knowledge, this is the ﬁrst study to report
an association between WCH and micro-
vascular complications in type 2 diabetic
patients.
The higher blood pressure peak dem-
onstrated during the exercise test could
be one example of how blood pressure
responds to daily stressors in subjects
with WCH. The WCH phenomenon may
indeed reﬂect an abnormal and vigorous
sympathetic response to environmental
stimuli,whichcanbeintheformofeither
mild physical activity or the presence of a
healthcareprofessional.Thisacuterisein
blood pressure levels could lead to glo-
merular and retinal damage. Patel et al.
(25) demonstrated increased retinal ﬂow
after a rise in blood pressure in diabetic
patients, suggesting that acute changes in
blood pressure have a deleterious impact
on retinal vessels. It is worth noting that
all of the blood pressure loads in patients
with WCH in our sample were higher
than those in the normotensive individu-
als, suggesting acute and repeated rises in
blood pressure levels, several times in the
course of 24 h, during ordinary activities
and probably also exercise.
The limitation of this report is mainly
the cross-sectional design, which pre-
vents the drawing of conclusions about
thecause-and-effectrelationshipbetween
WCHandtherenalandretinaloutcomes.
However, this limitation does not detract
from the main result of this study.
In summary, type 2 diabetic patients
with WCH have an increased risk for mi-
crovascular complications. These ﬁnd-
ings indicate that WCH is not a benign
situation in type 2 diabetic patients and
most likely represents a phenotype inter-
mediary between normotension and hy-
pertension. Randomized controlled trials
are needed to clarify the role of treatment
of WCH in preventing type 2 diabetes-
associated complications.
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